On Mar. 19, 2020, Roche is working with the FDA to initiate a randomised, double-blind, placebo-controlled Phase III clinical trial in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), to evaluate the safety and efficacy of Actemraﾮ/RoActemraﾮ (tocilizumab) plus standard of care in hospitalised adult patients with severe COVID-19 pneumonia compared to placebo plus standard of care.